Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q3 FY20 results · Oct–Dec 2019
Jubilant Pharmova reported revenue from operations of ₹2,315.21 crore (down 2.6% from Q3 FY19) and net profit of ₹203.38 crore (down 24.0% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,315.21 | 2,377.10 | −2.6% | 2,265.93 | +2.2% |
| Other income | 6.03 | 29.02 | −79.2% | 12.26 | −50.8% |
| Total income | 2,321.24 | 2,406.12 | −3.5% | 2,278.19 | +1.9% |
| Profit before tax | 293.32 | 355.61 | −17.5% | 292.23 | +0.4% |
| Net profit for the period | 203.38 | 267.52 | −24.0% | 249.39 | −18.4% |
| EPS, basic (₹) | 12.77 | 16.74 | −23.7% | 15.66 | −18.5% |
| Net margin (%) | 8.8 | 11.3 | 11.0 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 801.18 | 859.58 | −6.8% | 757.54 | +5.8% |
| Other income | 5.52 | 4.96 | +11.3% | 79.08 | −93.0% |
| Total income | 806.70 | 864.54 | −6.7% | 836.62 | −3.6% |
| Profit before tax | 34.96 | 52.38 | −33.3% | 106.20 | −67.1% |
| Net profit for the period | 34.63 | 36.70 | −5.6% | 143.07 | −75.8% |
| EPS, basic (₹) | 2.17 | 2.30 | −5.7% | 8.98 | −75.8% |
| Net margin (%) | 4.3 | 4.3 | 18.9 |
Consolidated
- Filed with BSE
- 31 Jan 2020, 18:14 IST
- Board meeting
- 31 Jan 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jan 2020, 18:14 IST
- Board meeting
- 31 Jan 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE